Scarica l'app Stockscreener
234.99
0.35%
-0.9759
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché AXSM Giù?
Forum
Previsione
Axsome Therapeutics Inc Borsa (AXSM) Ultime notizie
New AUVELITY depression data, sleep apnea study head to ASCP 2026 - Stock Titan
Axsome Therapeutics, Inc. $AXSM Shares Acquired by Legato Capital Management LLC - MarketBeat
Axsome Therapeutics stock hits all-time high at 236.84 USD By Investing.com - Investing.com Nigeria
Axsome Therapeutics Climbs Higher On Nasdaq Momentum - Kalkine Media
Technical Reactions to AXSM Trends in Macro Strategies - Stock Traders Daily
Axsome Therapeutics (NASDAQ:AXSM) Reaches New 1-Year HighShould You Buy? - MarketBeat
Axsome Therapeutics stock hits all-time high at 236.84 USD - Investing.com
AXSM Stock Price, Quote & Chart | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Axsome wins FDA label expansion for Auvelity in Alzheimer’s agitation - MSN
AXSM Technical Analysis | Trend, Signals & Chart Patterns | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
AXSM: June launch of new Alzheimer's agitation drug, expanded sales force, and robust pipeline progress - TradingView
Axsome Therapeutics (AXSM) price target increased by 18.66% to 272.70 - MSN
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: High Growth Potential with 18.69% Upside - DirectorsTalk Interviews
Why is Axsome (AXSM) down 6.6% since last earnings report? - MSN
Axsome projects Auvelity peak sales of at least $8B following Alzheimer's agitation approval and June launch - MSN
AXSM stock clocks best day in about 4 months on FDA greenlight for Alzheimer’s drug - MSN
Axsome Therapeutics bets on AUVELITY expansion with June Alzheimer's agitation launch - MSN
Axsome stock climbs on schizophrenia drug deal with Takeda - MSN
Axsome's Auvelity: A New Treatment For Agitation In Alzheimer's Disease (AXSM) - Seeking Alpha
AXSM Stock Chart | AXSOME THERAPEUTICS INC (NASDAQ:AXSM) - ChartMill
Axsome Therapeutics stock hits all-time high at 234.57 USD - Investing.com India
Axsome Therapeutics stock hits all-time high at 234.57 USD By Investing.com - Investing.com Nigeria
AXSM stock is rising today after Wall Street’s positive stance despite mixed Q1 – what's behind the optimism? - MSN
Axsome Therapeutics Bets on AUVELITY Expansion With June Alzheimer’s Agitation Launch - sharewise.com
Piper Sandler Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $258 - Moomoo
Strong drug sales lift Axsome revenue, but profit miss drags stock - MSN
Trading the Move, Not the Narrative: (AXSM) Edition - Stock Traders Daily
White & Case advises Takeda on divestment to Axsome Therapeutics - White & Case LLP
Axsome Therapeutics, Inc. (AXSM) Stock Analysis: Understanding the 24% Potential Upside in CNS Treatments - DirectorsTalk Interviews
Axsome Q1 2026 slides: 57% revenue surge, $18B peak sales target - Investing.com Nigeria
Axsome Q1 2026 slides: 57% revenue surge, $18B peak sales target By Investing.com - Investing.com South Africa
Earnings call transcript: Axsome Therapeutics Q1 2026 reveals mixed results By Investing.com - Investing.com Australia
Earnings call transcript: Axsome Therapeutics Q1 2026 reveals mixed results - Investing.com
The week in pharma: action, reaction and insight – week to May 8, 2026 - The Pharma Letter
Axsome Therapeutics, Inc. $AXSM Holdings Decreased by State of New Jersey Common Pension Fund D - MarketBeat
Mizuho Securities Maintains Axsome Therapeutics(AXSM.US) With Buy Rating, Maintains Target Price $310 - Moomoo
3 Stocks Poised to Disrupt the Healthcare Market by 2030 - The Motley Fool
Principal Financial Group Inc. Lowers Holdings in Axsome Therapeutics, Inc. $AXSM - MarketBeat
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):